Aimee DeGaetano Joins Vastrax as Global Head of Commercial and Clinical Affairs

Leading Clinical Research Organization Strengthens Expertise in Neurovascular Field


ANDOVER, Mass.–(BUSINESS WIRE)–Vastrax, a premier full-service Contract Research Organization (CRO) with a mission to expedite the development of cutting-edge technologies in the vascular market, proudly announces the appointment of Aimee DeGaetano as the Global Head of Commercial and Clinical Affairs.

“Our dedication to accelerating advancements in the vascular sector is unwavering, and Aimee’s appointment reinforces this commitment,” said Ryan Bouchard, President and CEO of Vastrax. “Aimee’s expertise aligns seamlessly with our mission, and we are thrilled to have her lead our Global Commercial Strategy and Clinical Affairs. Aimee’s appointment comes at a crucial juncture in Vastrax’s journey as we continue to lead the way in neurovascular clinical trials. Her expertise will significantly contribute to our efforts in helping our clients advance ground-breaking technological solutions that have the potential to transform the lives of patients worldwide.”

Aimee is a registered dietician (RD) and holds a master’s in public health (clinical epidemiology). She is currently completing a doctorate in health science at Eastern Virginia Medical School. She has held various leadership roles in medical technology companies, focusing on clinical trials, medical affairs, and key opinion leader engagement. Her unique blend of skills perfectly aligns with Vastrax’s multifaceted approach to driving efficient technology approvals.

“I am honored to contribute to Vastrax’s pivotal role in assisting our clients to expedite the introduction of groundbreaking vascular technologies,” commented Aimee DeGaetano. “Together, we will fortify our commitment to clinical trials, integrating novel innovations, strategies and technologies to enhance patient care and improve outcomes.”

About Vastrax, Inc.

Vastrax is a cutting-edge full-service Contract Research Organization specializing in expediting the development of cutting-edge technologies in the vascular market. With an expert team possessing over 100 years of combined clinical, commercial, and regulatory experience, Vastrax is at the forefront of pioneering innovations, delivering transformative products to market efficiently. For more information please visit us at www.vastrax.com and follow us on LinkedIn.

Contacts

Tara DiMilia

908-369-7168

Tara.DiMilia@tmstrat.com

Staff

Recent Posts

Daily Fit Notes Rolls Out Affordable Fitness Solutions for the Modern Lifestyle

Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…

2 days ago

WillowWood Rebrand by DD.NYC Wins Gold Anthem Award for Product and Innovation in 2024 Rebrand

MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…

2 days ago

Quantum Biopharma Announces Closing of Second Tranche

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…

2 days ago

Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

2 days ago